Blog

T cells

Preparing for Cell and Gene Therapy 3.0

Patient data is mission-critical data — especially in cell and gene therapy.

In cell and gene therapy (CGT), the patient is the process is the product. Patient and/or donor data is an essential part of manufacturing and delivery, in unique and complex ways. It is also fundamental to patient safety and product and process knowledge, providing the opportunity to reduce risk and accelerate development.

Read More
January 30, 2020

Data management for advanced therapies, Part 4: working with multiple stakeholders

Note: this post is the fourth in an eight-part series on data management strategies for personalized therapies, such as cell...

January 8, 2020

Data management for advanced therapies, Part 3: working with living cells

Note: this post is the third in an eight-part series on data management strategies for personalized therapies, such as cell...

December 17, 2019

WoVen, a podcast from Canaan featuring Amy DuRoss

One of Vineti’s board members, Nina Kjellson, General Partner, at Canaan started a podcast called WoVen, about women who venture. We’re excited to...

December 4, 2019

Data management for advanced therapies, Part 2: unique data features

Note: this post is the second of an eight-part series on data management strategies for personalized therapies, such as cell...

December 4, 2019

Data management for advanced therapies, Part 1: the need for new strategies

Note: this post is the first of an eight-part series on data management strategies for personalized therapies, such as cell...

November 15, 2019

Eight million pages, the Space Shuttle, and other highlights from BMWS 2019

If you’re producing cell therapy products for 10,000 patients a year, how many release tests will be required? If making...

November 6, 2019

More kaizen for cell and gene therapy

Today, Vineti is excited to announce a new partnership with a global contract manufacturing company serving cell and gene therapies — and...

October 30, 2019

Chain of Identity and Chain of Custody in personalized therapies — core differences from traditional pharma

In pharmaceutical manufacturing, Chain of Identity and Chain of Custody may not be new — but in advanced therapy manufacturing,...

October 17, 2019

Supply chain vs. value chain: need-to-know essentials

In a recent blog post about Quality Risk Management, we talked about the importance of considering the entire “value chain” when...

August 27, 2019

In September, here’s why it’s all about data management

Next month, my colleagues at Vineti and I will be speaking, writing, and presenting on a topic of critical importance...

August 8, 2019

Cell therapy and gene therapy news: updates from some of our biopharmaceutical partners

We’re always excited to support the innovation pursued by our biopharmaceutical partners as they work toward improved patient outcomes. Here...

July 10, 2019

Supply chain management readiness, Part 4: quality risk management

Note: this post is the last of a four-part series on supply chain planning for personalized therapies such as cell...